ATNM actiniumpharma.com: Operating Profitability

ATNM (Actinium Pharmaceuticals) - company brandmark

Actinium Pharmaceuticals (ATNM) seeks to commercialize leukemia radiotherapy, yet the lack of stable cash flow creates financial pressure. The operating margin helps resolve this dissonance, while 26.10 determines a fresh valuation metric. Fundamental stability is provided by leadership in creating radioisotope conjugates and a robust patent shield, which forms a significant barrier to entry for third-party players.

ATNM: Actinium Pharma Profitability of Operations 07/04/2022 - 11/20/2026

Analytical breakdowns for Actinium Pharmaceuticals

- share price and consensus valuation forecast:
- company stock capitalization data:
Fundamental company valuation:ATNM, Actinium Pharmaceuticals, Inc.
Core merchandise of actiniumpharma.com

The stability of Actinium Pharmaceuticals (ATNM) currently depends on the efficiency of managing clinical trial costs in the absence of revenue. This indicator reflects the share of operating profit before taxes and interest, allowing investors to assess operating leverage and the rate of cost growth, which is clearly confirmed by the operating margin trend when analyzing business scaling.